Loading…
1204 Improving lymphatic function to reduce B cell responses in lupus
BackgroundIn SLE, that ultraviolet radiation exposure can induce both photosensitive skin responses and increased autoantibody titers suggests a critical and targetable role for the communication from skin to draining lymph nodes in regulating lymph node B cell responses. Lymphatic vessels bring cel...
Saved in:
Published in: | Lupus science & medicine 2022-12, Vol.9 (Suppl 3), p.A88-A88 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | A88 |
container_issue | Suppl 3 |
container_start_page | A88 |
container_title | Lupus science & medicine |
container_volume | 9 |
creator | Ambler, William G Howlader, Mir Chalasani, Madhavi Latha S Seltzer, Ethan S Sim, JiHyun Shin, Jinyeon Schwartz, Noa Dasoveanu, Dragos Carballo, Camila B Sevim, Ecem Siddique, Salma Rodeo, Scott Erkan, Doruk Kataru, Raghu P Mehrara, Babak Lu, Theresa T |
description | BackgroundIn SLE, that ultraviolet radiation exposure can induce both photosensitive skin responses and increased autoantibody titers suggests a critical and targetable role for the communication from skin to draining lymph nodes in regulating lymph node B cell responses. Lymphatic vessels bring cells and signals from skin to draining lymph nodes to regulate immunity and dysfunction of lymphatic flow has the potential to alter immunity. Here we examine lymphatic flow function in SLE humans and models, showing that lymphatic flow from skin to lymph nodes is compromised. that improving lymphatic flow by manual lymphatic drainage (MLD) or in a transgenic model reduces lymph node B cell responses, and delineate the mechanistic underpinnings of how lymphatic flow modulates draining lymph node function.MethodsWe examined lymphatic vessel luminal area considered to be reflective of lymphatic flow function in healthy controls, SLE, and control disease (anti-phospholipid antibody+ non-SLE patients) by immunohistochemistry and image analysis. We examined lymphatic function and performed manual lymphatic drainage in both MRL/lpr and imiquimod-induced lupus models. Lymphatic function was assessed by Evans blue tissue clearance assays and lymph node function was assessed by mainly by flow cytometry. Lymphatic flow was improved by either manual lymphatic drainage, adapted to mice based on techniques used in humans, or in a transgenic PTENf/f Flt4-CreER model with increased lymphatic numbers and function.ResultsSLE patient skin showed increased lymphatic vessel lumen size in skin and multiple SLE mouse models showed reduced clearance of intradermally-injected Evans blue, both suggesting reduced lymphatic flow in SLE. Improving lymphatic flow by manual lymphatic drainage (MLD) or in imiquimod-treated PTENf/f Flt4-CreER mice reduced both cutaneous photosensitivity and lymph node germinal center and plasma cells.Mechanistically, improved flow restrains B cell responses by upregulating lymph node fibroblastic reticular cell CCL2, which modulates monocyte phenotype to limit germinal center and plasma cell numbers.ConclusionsOur results suggest a scenario whereby dysfunctional communication between the skin and the immune system alters lymph node function to modulate disease, point to a lymphatic flow-lymph node stromal axis as a therapeutic target, and suggest the possibility of manual lymphatic drainage, an existing treatment modality used in breast adjunctive treatment in S |
doi_str_mv | 10.1136/lupus-2022-lupus21century.86 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c52caa19cccc4fbdbea81d282fb9a8c9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_c52caa19cccc4fbdbea81d282fb9a8c9</doaj_id><sourcerecordid>2754589844</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1976-a189f1e644cf11e382f823075ecd2e37219cc9676547f3777f4c006edb3491a43</originalsourceid><addsrcrecordid>eNpVUMlKxDAYDoLgMM47BPTaMVuzHHVwGRjwoueQpsnY0jY1aYW5efFFfRLbGUE8_Qsf3wbANUZrjCm_acZ-TBlBhGTHlWDrumGMh7XkZ2BBUE4zKRS6AKuUaoQQJpgKiRbgERPEvj-_tm0fw0fV7WFzaPs3M1QW-rGzQxU6OAQYXTlaB--gdU0zXakPXXIJVh08Kl6Cc2-a5Fa_cwleH-5fNk_Z7vlxu7ndZQVWgmcGS-Wx44xZj7GjknhJKBK5syVxVBCsrFVc8JwJT4UQnlmEuCsLyhQ2jC7B9sRbBlPrPlatiQcdTKWPjxD32sTJfOO0zYk1Zia0lvmiLJyRuCSTZKGMtGriujpxTdHfR5cGXYcxdpN9TUTOcqkkmxXlCVW09R8AIz03r4_h9dy8_t-8lpz-AGpyf9I</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2754589844</pqid></control><display><type>article</type><title>1204 Improving lymphatic function to reduce B cell responses in lupus</title><source>BMJ Open Access Journals</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>PubMed Central</source><creator>Ambler, William G ; Howlader, Mir ; Chalasani, Madhavi Latha S ; Seltzer, Ethan S ; Sim, JiHyun ; Shin, Jinyeon ; Schwartz, Noa ; Dasoveanu, Dragos ; Carballo, Camila B ; Sevim, Ecem ; Siddique, Salma ; Rodeo, Scott ; Erkan, Doruk ; Kataru, Raghu P ; Mehrara, Babak ; Lu, Theresa T</creator><creatorcontrib>Ambler, William G ; Howlader, Mir ; Chalasani, Madhavi Latha S ; Seltzer, Ethan S ; Sim, JiHyun ; Shin, Jinyeon ; Schwartz, Noa ; Dasoveanu, Dragos ; Carballo, Camila B ; Sevim, Ecem ; Siddique, Salma ; Rodeo, Scott ; Erkan, Doruk ; Kataru, Raghu P ; Mehrara, Babak ; Lu, Theresa T</creatorcontrib><description>BackgroundIn SLE, that ultraviolet radiation exposure can induce both photosensitive skin responses and increased autoantibody titers suggests a critical and targetable role for the communication from skin to draining lymph nodes in regulating lymph node B cell responses. Lymphatic vessels bring cells and signals from skin to draining lymph nodes to regulate immunity and dysfunction of lymphatic flow has the potential to alter immunity. Here we examine lymphatic flow function in SLE humans and models, showing that lymphatic flow from skin to lymph nodes is compromised. that improving lymphatic flow by manual lymphatic drainage (MLD) or in a transgenic model reduces lymph node B cell responses, and delineate the mechanistic underpinnings of how lymphatic flow modulates draining lymph node function.MethodsWe examined lymphatic vessel luminal area considered to be reflective of lymphatic flow function in healthy controls, SLE, and control disease (anti-phospholipid antibody+ non-SLE patients) by immunohistochemistry and image analysis. We examined lymphatic function and performed manual lymphatic drainage in both MRL/lpr and imiquimod-induced lupus models. Lymphatic function was assessed by Evans blue tissue clearance assays and lymph node function was assessed by mainly by flow cytometry. Lymphatic flow was improved by either manual lymphatic drainage, adapted to mice based on techniques used in humans, or in a transgenic PTENf/f Flt4-CreER model with increased lymphatic numbers and function.ResultsSLE patient skin showed increased lymphatic vessel lumen size in skin and multiple SLE mouse models showed reduced clearance of intradermally-injected Evans blue, both suggesting reduced lymphatic flow in SLE. Improving lymphatic flow by manual lymphatic drainage (MLD) or in imiquimod-treated PTENf/f Flt4-CreER mice reduced both cutaneous photosensitivity and lymph node germinal center and plasma cells.Mechanistically, improved flow restrains B cell responses by upregulating lymph node fibroblastic reticular cell CCL2, which modulates monocyte phenotype to limit germinal center and plasma cell numbers.ConclusionsOur results suggest a scenario whereby dysfunctional communication between the skin and the immune system alters lymph node function to modulate disease, point to a lymphatic flow-lymph node stromal axis as a therapeutic target, and suggest the possibility of manual lymphatic drainage, an existing treatment modality used in breast adjunctive treatment in SLE.</description><identifier>EISSN: 2053-8790</identifier><identifier>DOI: 10.1136/lupus-2022-lupus21century.86</identifier><language>eng</language><publisher>London: Lupus Foundation of America</publisher><subject>Lupus ; Lupus-Targeted Therapeutics ; Lymphatic system</subject><ispartof>Lupus science & medicine, 2022-12, Vol.9 (Suppl 3), p.A88-A88</ispartof><rights>Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2754589844/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2754589844?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590,55350,75126,77660,77686</link.rule.ids></links><search><creatorcontrib>Ambler, William G</creatorcontrib><creatorcontrib>Howlader, Mir</creatorcontrib><creatorcontrib>Chalasani, Madhavi Latha S</creatorcontrib><creatorcontrib>Seltzer, Ethan S</creatorcontrib><creatorcontrib>Sim, JiHyun</creatorcontrib><creatorcontrib>Shin, Jinyeon</creatorcontrib><creatorcontrib>Schwartz, Noa</creatorcontrib><creatorcontrib>Dasoveanu, Dragos</creatorcontrib><creatorcontrib>Carballo, Camila B</creatorcontrib><creatorcontrib>Sevim, Ecem</creatorcontrib><creatorcontrib>Siddique, Salma</creatorcontrib><creatorcontrib>Rodeo, Scott</creatorcontrib><creatorcontrib>Erkan, Doruk</creatorcontrib><creatorcontrib>Kataru, Raghu P</creatorcontrib><creatorcontrib>Mehrara, Babak</creatorcontrib><creatorcontrib>Lu, Theresa T</creatorcontrib><title>1204 Improving lymphatic function to reduce B cell responses in lupus</title><title>Lupus science & medicine</title><addtitle>Lupus Sci Med</addtitle><description>BackgroundIn SLE, that ultraviolet radiation exposure can induce both photosensitive skin responses and increased autoantibody titers suggests a critical and targetable role for the communication from skin to draining lymph nodes in regulating lymph node B cell responses. Lymphatic vessels bring cells and signals from skin to draining lymph nodes to regulate immunity and dysfunction of lymphatic flow has the potential to alter immunity. Here we examine lymphatic flow function in SLE humans and models, showing that lymphatic flow from skin to lymph nodes is compromised. that improving lymphatic flow by manual lymphatic drainage (MLD) or in a transgenic model reduces lymph node B cell responses, and delineate the mechanistic underpinnings of how lymphatic flow modulates draining lymph node function.MethodsWe examined lymphatic vessel luminal area considered to be reflective of lymphatic flow function in healthy controls, SLE, and control disease (anti-phospholipid antibody+ non-SLE patients) by immunohistochemistry and image analysis. We examined lymphatic function and performed manual lymphatic drainage in both MRL/lpr and imiquimod-induced lupus models. Lymphatic function was assessed by Evans blue tissue clearance assays and lymph node function was assessed by mainly by flow cytometry. Lymphatic flow was improved by either manual lymphatic drainage, adapted to mice based on techniques used in humans, or in a transgenic PTENf/f Flt4-CreER model with increased lymphatic numbers and function.ResultsSLE patient skin showed increased lymphatic vessel lumen size in skin and multiple SLE mouse models showed reduced clearance of intradermally-injected Evans blue, both suggesting reduced lymphatic flow in SLE. Improving lymphatic flow by manual lymphatic drainage (MLD) or in imiquimod-treated PTENf/f Flt4-CreER mice reduced both cutaneous photosensitivity and lymph node germinal center and plasma cells.Mechanistically, improved flow restrains B cell responses by upregulating lymph node fibroblastic reticular cell CCL2, which modulates monocyte phenotype to limit germinal center and plasma cell numbers.ConclusionsOur results suggest a scenario whereby dysfunctional communication between the skin and the immune system alters lymph node function to modulate disease, point to a lymphatic flow-lymph node stromal axis as a therapeutic target, and suggest the possibility of manual lymphatic drainage, an existing treatment modality used in breast adjunctive treatment in SLE.</description><subject>Lupus</subject><subject>Lupus-Targeted Therapeutics</subject><subject>Lymphatic system</subject><issn>2053-8790</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpVUMlKxDAYDoLgMM47BPTaMVuzHHVwGRjwoueQpsnY0jY1aYW5efFFfRLbGUE8_Qsf3wbANUZrjCm_acZ-TBlBhGTHlWDrumGMh7XkZ2BBUE4zKRS6AKuUaoQQJpgKiRbgERPEvj-_tm0fw0fV7WFzaPs3M1QW-rGzQxU6OAQYXTlaB--gdU0zXakPXXIJVh08Kl6Cc2-a5Fa_cwleH-5fNk_Z7vlxu7ndZQVWgmcGS-Wx44xZj7GjknhJKBK5syVxVBCsrFVc8JwJT4UQnlmEuCsLyhQ2jC7B9sRbBlPrPlatiQcdTKWPjxD32sTJfOO0zYk1Zia0lvmiLJyRuCSTZKGMtGriujpxTdHfR5cGXYcxdpN9TUTOcqkkmxXlCVW09R8AIz03r4_h9dy8_t-8lpz-AGpyf9I</recordid><startdate>20221214</startdate><enddate>20221214</enddate><creator>Ambler, William G</creator><creator>Howlader, Mir</creator><creator>Chalasani, Madhavi Latha S</creator><creator>Seltzer, Ethan S</creator><creator>Sim, JiHyun</creator><creator>Shin, Jinyeon</creator><creator>Schwartz, Noa</creator><creator>Dasoveanu, Dragos</creator><creator>Carballo, Camila B</creator><creator>Sevim, Ecem</creator><creator>Siddique, Salma</creator><creator>Rodeo, Scott</creator><creator>Erkan, Doruk</creator><creator>Kataru, Raghu P</creator><creator>Mehrara, Babak</creator><creator>Lu, Theresa T</creator><general>Lupus Foundation of America</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>9YT</scope><scope>ACMMV</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>DOA</scope></search><sort><creationdate>20221214</creationdate><title>1204 Improving lymphatic function to reduce B cell responses in lupus</title><author>Ambler, William G ; Howlader, Mir ; Chalasani, Madhavi Latha S ; Seltzer, Ethan S ; Sim, JiHyun ; Shin, Jinyeon ; Schwartz, Noa ; Dasoveanu, Dragos ; Carballo, Camila B ; Sevim, Ecem ; Siddique, Salma ; Rodeo, Scott ; Erkan, Doruk ; Kataru, Raghu P ; Mehrara, Babak ; Lu, Theresa T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1976-a189f1e644cf11e382f823075ecd2e37219cc9676547f3777f4c006edb3491a43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Lupus</topic><topic>Lupus-Targeted Therapeutics</topic><topic>Lymphatic system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ambler, William G</creatorcontrib><creatorcontrib>Howlader, Mir</creatorcontrib><creatorcontrib>Chalasani, Madhavi Latha S</creatorcontrib><creatorcontrib>Seltzer, Ethan S</creatorcontrib><creatorcontrib>Sim, JiHyun</creatorcontrib><creatorcontrib>Shin, Jinyeon</creatorcontrib><creatorcontrib>Schwartz, Noa</creatorcontrib><creatorcontrib>Dasoveanu, Dragos</creatorcontrib><creatorcontrib>Carballo, Camila B</creatorcontrib><creatorcontrib>Sevim, Ecem</creatorcontrib><creatorcontrib>Siddique, Salma</creatorcontrib><creatorcontrib>Rodeo, Scott</creatorcontrib><creatorcontrib>Erkan, Doruk</creatorcontrib><creatorcontrib>Kataru, Raghu P</creatorcontrib><creatorcontrib>Mehrara, Babak</creatorcontrib><creatorcontrib>Lu, Theresa T</creatorcontrib><collection>BMJ Open Access Journals</collection><collection>BMJ Journals:Open Access</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Lupus science & medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ambler, William G</au><au>Howlader, Mir</au><au>Chalasani, Madhavi Latha S</au><au>Seltzer, Ethan S</au><au>Sim, JiHyun</au><au>Shin, Jinyeon</au><au>Schwartz, Noa</au><au>Dasoveanu, Dragos</au><au>Carballo, Camila B</au><au>Sevim, Ecem</au><au>Siddique, Salma</au><au>Rodeo, Scott</au><au>Erkan, Doruk</au><au>Kataru, Raghu P</au><au>Mehrara, Babak</au><au>Lu, Theresa T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1204 Improving lymphatic function to reduce B cell responses in lupus</atitle><jtitle>Lupus science & medicine</jtitle><stitle>Lupus Sci Med</stitle><date>2022-12-14</date><risdate>2022</risdate><volume>9</volume><issue>Suppl 3</issue><spage>A88</spage><epage>A88</epage><pages>A88-A88</pages><eissn>2053-8790</eissn><abstract>BackgroundIn SLE, that ultraviolet radiation exposure can induce both photosensitive skin responses and increased autoantibody titers suggests a critical and targetable role for the communication from skin to draining lymph nodes in regulating lymph node B cell responses. Lymphatic vessels bring cells and signals from skin to draining lymph nodes to regulate immunity and dysfunction of lymphatic flow has the potential to alter immunity. Here we examine lymphatic flow function in SLE humans and models, showing that lymphatic flow from skin to lymph nodes is compromised. that improving lymphatic flow by manual lymphatic drainage (MLD) or in a transgenic model reduces lymph node B cell responses, and delineate the mechanistic underpinnings of how lymphatic flow modulates draining lymph node function.MethodsWe examined lymphatic vessel luminal area considered to be reflective of lymphatic flow function in healthy controls, SLE, and control disease (anti-phospholipid antibody+ non-SLE patients) by immunohistochemistry and image analysis. We examined lymphatic function and performed manual lymphatic drainage in both MRL/lpr and imiquimod-induced lupus models. Lymphatic function was assessed by Evans blue tissue clearance assays and lymph node function was assessed by mainly by flow cytometry. Lymphatic flow was improved by either manual lymphatic drainage, adapted to mice based on techniques used in humans, or in a transgenic PTENf/f Flt4-CreER model with increased lymphatic numbers and function.ResultsSLE patient skin showed increased lymphatic vessel lumen size in skin and multiple SLE mouse models showed reduced clearance of intradermally-injected Evans blue, both suggesting reduced lymphatic flow in SLE. Improving lymphatic flow by manual lymphatic drainage (MLD) or in imiquimod-treated PTENf/f Flt4-CreER mice reduced both cutaneous photosensitivity and lymph node germinal center and plasma cells.Mechanistically, improved flow restrains B cell responses by upregulating lymph node fibroblastic reticular cell CCL2, which modulates monocyte phenotype to limit germinal center and plasma cell numbers.ConclusionsOur results suggest a scenario whereby dysfunctional communication between the skin and the immune system alters lymph node function to modulate disease, point to a lymphatic flow-lymph node stromal axis as a therapeutic target, and suggest the possibility of manual lymphatic drainage, an existing treatment modality used in breast adjunctive treatment in SLE.</abstract><cop>London</cop><pub>Lupus Foundation of America</pub><doi>10.1136/lupus-2022-lupus21century.86</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | EISSN: 2053-8790 |
ispartof | Lupus science & medicine, 2022-12, Vol.9 (Suppl 3), p.A88-A88 |
issn | 2053-8790 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_c52caa19cccc4fbdbea81d282fb9a8c9 |
source | BMJ Open Access Journals; Publicly Available Content Database (Proquest) (PQ_SDU_P3); PubMed Central |
subjects | Lupus Lupus-Targeted Therapeutics Lymphatic system |
title | 1204 Improving lymphatic function to reduce B cell responses in lupus |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T05%3A12%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1204%E2%80%85Improving%20lymphatic%20function%20to%20reduce%20B%20cell%20responses%20in%20lupus&rft.jtitle=Lupus%20science%20&%20medicine&rft.au=Ambler,%20William%20G&rft.date=2022-12-14&rft.volume=9&rft.issue=Suppl%203&rft.spage=A88&rft.epage=A88&rft.pages=A88-A88&rft.eissn=2053-8790&rft_id=info:doi/10.1136/lupus-2022-lupus21century.86&rft_dat=%3Cproquest_doaj_%3E2754589844%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b1976-a189f1e644cf11e382f823075ecd2e37219cc9676547f3777f4c006edb3491a43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2754589844&rft_id=info:pmid/&rfr_iscdi=true |